Altitude
The "Nibble It" Problem: What Your Doctor Doesn't Have to Tell You About Off-Label Prescriptions
Editorial

The "Nibble It" Problem: What Your Doctor Doesn't Have to Tell You About Off-Label Prescriptions

Roughly half of all US prescriptions are for uses the FDA never approved or studied at that dose. There's no legal requirement to tell you that. We looked at three of the most common ones.

Nathan Richardson • Sep 26, 2026

About half of all US prescriptions are written off-label — for a use, population, or dose the drug was never formally studied for. There's no FDA requirement that your doctor tell you that. We looked at three of the most commonly off-label-prescribed psychiatric drugs and what the side-effect data actually shows at the doses people are actually taking.

One reader told us about the instruction their doctor gave them for a sleep prescription: "nibble it" — break the tablet down, take a fraction of the smallest dose the pharmacy sells, and see how it goes. It's not an unusual instruction. It's also a real signal of something bigger: the drug in question doesn't come in a dose small enough for what it's actually being prescribed for, because it was never approved for that use in the first place. That reader later woke up gasping for air in the night — a real, reported symptom we can't causally pin on the drug with any confidence, and shouldn't try to. What we can say with confidence is that this is exactly the kind of side effect that off-label prescribing at improvised doses makes harder to track, because nobody ran the trial that would have caught it.

Half of Everything, Disclosed to No One

Off-label prescriptions account for roughly half of all prescriptions written in the US today. It's completely legal — once the FDA approves a drug for one use, a physician can prescribe it for any use they judge medically appropriate. What's not required is telling the patient. There is currently no FDA rule mandating that a doctor disclose off-label status before prescribing, even though medical ethics literature has argued for decades that informed consent should require it. In psychiatry specifically, this isn't a fringe practice — 75% of antidepressant prescriptions are for off-label uses, sertraline is prescribed off-label roughly 67% of the time, and amitriptyline hits 81%.

Three Drugs, Improvised Doses

Trazodone. FDA-approved for major depressive disorder, at doses starting around 150mg. Its dominant real-world use today is nothing like that: low-dose, off-label, for sleep. Trazodone doesn't come in a tablet small enough for that job — the smallest strength is 50mg — so the routine clinical instruction is to split it, often into quarters, to land somewhere around 12.5-25mg. The American Academy of Sleep Medicine recommends against using it for chronic insomnia specifically because the evidence at that improvised dose is thin. To be fair to the drug: most published data on trazodone and breathing actually points toward benefit, not harm — several studies show it can lower the apnea/hypopnea index in obstructive sleep apnea rather than worsen it. That's the honest state of the evidence, even though it doesn't match every patient's individual experience.

Gabapentin. More than 99% of gabapentin prescriptions today are off-label. Roughly 83% of that off-label volume is for pain management alone; smaller slices go to anxiety and insomnia, conditions it was never designed or approved for. No randomized controlled trial has ever established its efficacy for generalized anxiety disorder. The FDA label's serious-but-rare adverse events include slowed or shallow breathing — a real risk that climbs meaningfully when gabapentin is combined with other sedating drugs, which is precisely how it tends to get stacked in real-world psychiatric prescribing.

Quetiapine (Seroquel). Three-quarters of new prescriptions are off-label, and in a recent primary-care study, sleep problems were the reason for nearly half of them — at 25-50mg, a small fraction of its approved antipsychotic dose range. The catch: low-dose quetiapine doesn't neutralize its real risks — weight gain, metabolic disease, heart-rhythm abnormalities. Multiple studies found physicians assumed the low dose was inherently safe and skipped the monitoring that's actually recommended at any dose.

The Disclosure Gap, Named

Put next to each other, the pattern is consistent: high off-label volume, doses improvised by tablet-splitting or by borrowing from a different indication entirely, and side-effect data that was generated at a different dose, in a different population, for a different condition than the one actually being treated. None of that makes off-label prescribing wrong — accumulated clinical experience is real evidence, and rewriting a formal trial for every dose variation isn't realistic. But it does mean the side-effect conversation patients get is often a doctor's best clinical judgment, not a disclosed number from a study. Compare that to DT120's own trial disclosure: a 37% nausea rate, published in a topline press release, at the exact dose people are actually being given. Off-label prescribing has never had to clear that bar, because the FDA never asked it to.

This is analysis and reporting, not medical advice. Do not stop, split, or adjust the dose of any prescribed medication without talking to your prescriber. Individual reported symptoms described here are anecdotal and are not presented as an established causal link to any specific drug.

Sources

← Back to Journal